Moreover, anti-TNFα treatment infliximab causes an increase in circulating non-classical monocytes in Crohn's disease patients (55), along with an increase in all CD16+ monocytes in rheumatoid arthritis patients (56). This evidence concerns the gene TNF and Crohn disease.